Jingjing Jiang
Vice President, Translational Research Revolution Medicines
Jingjing is an oncology scientist with nearly two decades of industry experience spanning translational research, in vivo pharmacology, functional genomics, and drug development. Currently, Jingjing serves as Vice President of Translational Research at Revolution Medicines, where she build and lead the cancer pharmacology and translational research organization across our RAS-targeted therapy portfolio.
Seminars
Wednesday 9th September 2026
Targeting Oncogenic RAS With Tri-Complex RAS(ON) Inhibitors
5:00 pm
- New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors
- Exploring strategic combination approaches to amplify efficacy and expand therapeutic reach, building on emerging insights across RAS driven tumor biology
- Showcasing a major year of clinical progress in the field
Tuesday 8th September 2026
Panel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?
1:00 pm
- How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
- Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
- How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?
